References
- BlüherMAdipose tissue dysfunction contributes to obesity related metabolic diseasesBest Pract Res Clin Endocrinol Metab201327216317723731879
- FoleyJEJordanJOverall weight neutrality associated with the DPP-4 inhibitor vildagliptin: mechanistic basis and clinical experienceVasc Health Risk Manag2010654154820730070
- FerranniniERamosSJSalsaliATangWListJFDapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trialDiabetes Care201033102217222420566676
- StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab201315437238223279307
- DejagerSSchweizerAFoleyJEEvidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitusVasc Health Risk Manag2012833934822661900
- MatikainenMMänttäriSSchweizerAVildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetesDiabetologia20064992049205716816950
- BoschmannMEngeliSBudziarekPDipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patientsJ Clin Endocrinol Metab200994384685219088168
- KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med2002346639340311832527
- DeFronzoRARatnerREHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care20052851092110015855572
- EMA/374133/2013 Committee for Medicinal Products for Human UseAssessment report. Canagliflozin Procedure No EMEA/H/C/002649/0000 (2013; page 50) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdfAccessed August 27, 2014